Home

Innovative Biopharmaceutical Compound Synthesis

Heparinex, L.L.C. is a biopharmaceutical company focused on the novel recombinant synthesis of compounds for (1) the growing anticoagulation market and associated markets and (2) the drug delivery market. Leading carbohydrate chemist/glycobiologist Dr. Paul DeAngelis originally discovered and patented Heparinex’s core technology platforms of proprietary carbohydrate production.

The company’s core platforms employ:

A. Bacterial production techniques
B. In vitro defined polymer syntheses to provide uniquely controlled
    non-animal sources of heparinoid compounds for drug discovery,
    therapeutic formulations and medical device applications

Commercial Applications in Multiple High-Yield Industries

Heparinex’s proprietary carbohydrate production platform technologies provide applications for multiple high-yield industries including:

• Drug conjugation/PEG (poly[ethylene glycol]) substitute
• Pharmaceutical/anticoagulation
• Drug development
• Bulk manufacturing/fermentation processes
• Medical device coatings
• Cosmetics
• Reconstructive surgery
• Novel autoimmune/infectious disease/cancer drug discovery

Heparinex is actively pursuing collaborative partnerships in the specific areas of medical device coatings; novel autoimmune/infectious disease/cancer drug discovery; and enhancing therapies with an improved PEG Substitute.

Visit related companies Hyalose L.L.C, Choncept L.L.C. and
Pure Protein, L.L.C.